Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ACAD
ACAD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ACAD News
Acadia Pharmaceuticals to Present Multiple Data at AAN Annual Meeting
3d ago
Newsfilter
Acadia Launches DAYBUE STIX Powder for Rett Syndrome Treatment
Apr 07 2026
Newsfilter
BofA Upgrades Acadia Pharmaceuticals to Buy Amid Price Pullback
Mar 25 2026
seekingalpha
Latest Rating Changes on Wall Street
Mar 25 2026
CNBC
Neuren and Acadia Request Re-examination for Rett Syndrome Drug
Mar 03 2026
NASDAQ.COM
Aardvark Pauses PWS Trial, Shares Plunge 53%
Feb 28 2026
stocktwits
ACADIA Pharmaceuticals Reports Strong Q4 2025 Earnings with $1 Billion Annual Revenue
Feb 26 2026
seekingalpha
ACADIA (ACAD) Q4 2025 Earnings Call Transcript
Feb 26 2026
NASDAQ.COM
Acadia Pharma to Announce Q4 Earnings on February 25
Feb 24 2026
seekingalpha
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
Feb 23 2026
Yahoo Finance
Wall Street Analysts Adjust Ratings on Key Stocks
Feb 23 2026
Benzinga
Analysts Recommend Innovative Healthcare Stocks
Feb 18 2026
Yahoo Finance
EMA Committee Votes Against Acadia's Trofinetide Application
Feb 03 2026
Benzinga
Acadia Pharmaceuticals Shares Drop Over 8% After EMA Negative Trend Vote
Feb 02 2026
stocktwits
Acadia Pharmaceuticals to Present at 2026 J.P. Morgan Healthcare Conference
Dec 18 2025
Newsfilter
Acadia Receives FDA Approval for DAYBUE STIX Treatment of Rett Syndrome
Dec 12 2025
Newsfilter
Show More News
